English

VIVOS THERAPEUTICS, INC.

EDGAR

VVOS Current report (8-K) · filed 2026-10-21

Annual consolidated revenue for 2025: about USD 17.44M, using the latest reported figures. The previous period, 2024, was about USD 15.03M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5.15 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 5153000 USD Source

Operating margin

-93.63%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -4825000 USD Source
Revenue: 5153000 USD Source

Operating cash flow

-3.2 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -9200000 USD Source
Operating Cash Flow: -6000000 USD Source

Free cash flow

-3.62 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -9200000 USD Source
Operating Cash Flow: -6000000 USD Source
Capital Expenditure: 434000 USD Source
Capital Expenditure: 18000 USD Source

Cash and cash equivalents: 1.8 million USD 2026-06-30 Source
Exact value

1800000 USD
Long-term debt including current maturities: 582 thousand USD 2026-06-30 Source
Exact value

582000 USD
Shares outstanding: 14.5 million shares 2026-06-30 Source
Exact value

14531617 shares

Reported share-count change

98.39% · 7.21 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

7324807 shares · 2025-06-30· Source
14531617 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

20.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 6783000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 17443000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 13619000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 5141000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 5153000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-25.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -5400000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -21200000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -14276000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -7700000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -5500000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-21.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2025-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+16%

Prior period

USD 15.03 million

2024-01-01 – 2024-12-31
Current period

USD 17.44 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

17443000 − 15031000 = 2412000 USD

15031000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
17443000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Year-over-year change in Revenue: 2412000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 17443000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#2070364 Filing: 000149315226016854 Input fundies:Revenue: 15031000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#2070773 Filing: 000149315226016854
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 10.1 million

Prior period

−USD 11.1 million

2024-01-01 – 2024-12-31
Current period

−USD 21.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-21200000 − -11100000 = -10100000 USD

-11100000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-21200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Year-over-year change in Net income: -10100000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -21200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1528753 Filing: 000149315226016854 Input fundies:NetIncome: -11100000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1529099 Filing: 000149315226016854
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.6 million

Prior period

−USD 12.7 million

2024-01-01 – 2024-12-31
Current period

−USD 15.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-15300000 − -12700000 = -2600000 USD

-12700000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-15300000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Year-over-year change in Operating cash flow: -2600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -15300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530439 Filing: 000149315226016854 Input fundies:OperatingCashFlow: -12700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530840 Filing: 000149315226016854
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+312.1%

Prior period

USD 568,000

2024-01-01 – 2024-12-31
Current period

USD 2.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2341000 − 568000 = 1773000 USD

568000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2341000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Year-over-year change in Capital expenditure: 1773000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2341000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1380932 Filing: 000149315226016854 Input fundies:CapitalExpenditure: 568000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1381280 Filing: 000149315226016854
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 17.44 million 100% of revenue
Cost of revenue USD 6.9 million 40% of revenue
Operating expenses USD 30.44 million 174% of revenue
Operating income −USD 19.89 million −114% of revenue
Tax, interest and other Derived USD 1.31 million 7.5% of revenue
Net income −USD 21.2 million −122% of revenue

Cash

Operating cash flow −USD 15.3 million −88% of revenue
Capital expenditure USD 2.34 million 13% of revenue
Free cash flow Derived −USD 17.64 million −101% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 193% of revenue.
2020 Operating loss: operating costs were 192% of revenue.
2021 Operating loss: operating costs were 221% of revenue.
2022 Operating loss: operating costs were 256% of revenue.
2023 Operating loss: operating costs were 225% of revenue.
2024 Operating loss: operating costs were 174% of revenue.
2025 Operating loss: operating costs were 214% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	11393277	21970510 Derived	-10577233	177086 Derived	-10754319	-5516079 Derived	Source 2019-01-01 – 2019-12-31: 11393277 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -10577233 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -10754319 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -5340480 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 175599 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	13066000	25106000 Derived	-12040000	17000 Derived	-12057000	-5820000 Derived	Source 2020-01-01 – 2020-12-31: 13066000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -12040000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -12057000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -5700000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 120000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	16885000	37267000 Derived	-20382000	-94000 Derived	-20288000	-18131000 Derived	Source 2021-01-01 – 2021-12-31: 16885000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -20382000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -20288000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -15735000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2396000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	16024000	41055000 Derived	-25031000	-1186000 Derived	-23845000	-20524000 Derived	Source 2022-01-01 – 2022-12-31: 16024000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -25031000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -23845000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -19600000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 924000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	13801000	31097000 Derived	-17296000	-3713000 Derived	-13583000	-12703000 Derived	Source 2023-01-01 – 2023-12-31: 13801000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -17296000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -13583000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -11900000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 803000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	15031000	26202000 Derived	-11171000	-71000 Derived	-11100000	-13268000 Derived	Source 2024-01-01 – 2024-12-31: 15031000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -11171000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -11100000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -12700000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 568000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	17443000	37337000 Derived	-19894000	1306000 Derived	-21200000	-17641000 Derived	Source 2025-01-01 – 2025-12-31: 17443000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -19894000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -21200000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -15300000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2341000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 17.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	11393277	Revenue: 11393277 Open source
20202020-12-31	Revenue	13066000	Revenue: 13066000 Open source
20212021-12-31	Revenue	16885000	Revenue: 16885000 Open source
20222022-12-31	Revenue	16024000	Revenue: 16024000 Open source
20232023-12-31	Revenue	13801000	Revenue: 13801000 Open source
20242024-12-31	Revenue	15031000	Revenue: 15031000 Open source
20252025-12-31	Revenue	17443000	Revenue: 17443000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

16% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 11393277 Open source
20202020-12-31	Year over year	14.7%	Revenue: 13066000 Open source Revenue: 11393277 Open source
20212021-12-31	Year over year	29.2%	Revenue: 16885000 Open source Revenue: 13066000 Open source
20222022-12-31	Year over year	-5.1%	Revenue: 16024000 Open source Revenue: 16885000 Open source
20232023-12-31	Year over year	-13.9%	Revenue: 13801000 Open source Revenue: 16024000 Open source
20242024-12-31	Year over year	8.9%	Revenue: 15031000 Open source Revenue: 13801000 Open source
20252025-12-31	Year over year	16%	Revenue: 17443000 Open source Revenue: 15031000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -114.1% 2025

Net margin -121.5% 2025

Free cash flow margin -101.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-92.8%	Operating Income: -10577233 Open source Revenue: 11393277 Open source
20202020-12-31	Operating margin	-92.1%	Operating Income: -12040000 Open source Revenue: 13066000 Open source
20212021-12-31	Operating margin	-120.7%	Operating Income: -20382000 Open source Revenue: 16885000 Open source
20222022-12-31	Operating margin	-156.2%	Operating Income: -25031000 Open source Revenue: 16024000 Open source
20232023-12-31	Operating margin	-125.3%	Operating Income: -17296000 Open source Revenue: 13801000 Open source
20242024-12-31	Operating margin	-74.3%	Operating Income: -11171000 Open source Revenue: 15031000 Open source
20252025-12-31	Operating margin	-114.1%	Operating Income: -19894000 Open source Revenue: 17443000 Open source
20192019-12-31	Net margin	-94.4%	Net Income: -10754319 Open source Revenue: 11393277 Open source
20202020-12-31	Net margin	-92.3%	Net Income: -12057000 Open source Revenue: 13066000 Open source
20212021-12-31	Net margin	-120.2%	Net Income: -20288000 Open source Revenue: 16885000 Open source
20222022-12-31	Net margin	-148.8%	Net Income: -23845000 Open source Revenue: 16024000 Open source
20232023-12-31	Net margin	-98.4%	Net Income: -13583000 Open source Revenue: 13801000 Open source
20242024-12-31	Net margin	-73.8%	Net Income: -11100000 Open source Revenue: 15031000 Open source
20252025-12-31	Net margin	-121.5%	Net Income: -21200000 Open source Revenue: 17443000 Open source
20192019-12-31	Free cash flow margin	-48.4%	Revenue: 11393277 Open source Operating Cash Flow: -5340480 Open source Capital Expenditure: 175599 Open source
20202020-12-31	Free cash flow margin	-44.5%	Revenue: 13066000 Open source Operating Cash Flow: -5700000 Open source Capital Expenditure: 120000 Open source
20212021-12-31	Free cash flow margin	-107.4%	Revenue: 16885000 Open source Operating Cash Flow: -15735000 Open source Capital Expenditure: 2396000 Open source
20222022-12-31	Free cash flow margin	-128.1%	Revenue: 16024000 Open source Operating Cash Flow: -19600000 Open source Capital Expenditure: 924000 Open source
20232023-12-31	Free cash flow margin	-92%	Revenue: 13801000 Open source Operating Cash Flow: -11900000 Open source Capital Expenditure: 803000 Open source
20242024-12-31	Free cash flow margin	-88.3%	Revenue: 15031000 Open source Operating Cash Flow: -12700000 Open source Capital Expenditure: 568000 Open source
20252025-12-31	Free cash flow margin	-101.1%	Revenue: 17443000 Open source Operating Cash Flow: -15300000 Open source Capital Expenditure: 2341000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -15.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-5340480	Operating Cash Flow: -5340480 Open source
20202020-12-31	Operating cash flow	-5700000	Operating Cash Flow: -5700000 Open source
20212021-12-31	Operating cash flow	-15735000	Operating Cash Flow: -15735000 Open source
20222022-12-31	Operating cash flow	-19600000	Operating Cash Flow: -19600000 Open source
20232023-12-31	Operating cash flow	-11900000	Operating Cash Flow: -11900000 Open source
20242024-12-31	Operating cash flow	-12700000	Operating Cash Flow: -12700000 Open source
20252025-12-31	Operating cash flow	-15300000	Operating Cash Flow: -15300000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -17.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-5516079	Operating Cash Flow: -5340480 Open source Capital Expenditure: 175599 Open source
20202020-12-31	Free cash flow	-5820000	Operating Cash Flow: -5700000 Open source Capital Expenditure: 120000 Open source
20212021-12-31	Free cash flow	-18131000	Operating Cash Flow: -15735000 Open source Capital Expenditure: 2396000 Open source
20222022-12-31	Free cash flow	-20524000	Operating Cash Flow: -19600000 Open source Capital Expenditure: 924000 Open source
20232023-12-31	Free cash flow	-12703000	Operating Cash Flow: -11900000 Open source Capital Expenditure: 803000 Open source
20242024-12-31	Free cash flow	-13268000	Operating Cash Flow: -12700000 Open source Capital Expenditure: 568000 Open source
20252025-12-31	Free cash flow	-17641000	Operating Cash Flow: -15300000 Open source Capital Expenditure: 2341000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

106.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	121.5%	Total Liabilities: 9177929 Open source Total Assets: 7551537 Open source
20202020-12-31	Liabilities / assets	33.2%	Total Liabilities: 8410000 Open source Total Assets: 25327000 Open source
20212021-12-31	Liabilities / assets	24.2%	Total Liabilities: 8150000 Open source Total Assets: 33689000 Open source
20222022-12-31	Liabilities / assets	65%	Total Liabilities: 8919000 Open source Total Assets: 13720000 Open source
20232023-12-31	Liabilities / assets	96.2%	Total Liabilities: 10319000 Open source Total Assets: 10730000 Open source
20242024-12-31	Liabilities / assets	48%	Total Liabilities: 7330000 Open source Total Assets: 15284000 Open source
20252025-12-31	Liabilities / assets	106.2%	Total Liabilities: 26702000 Open source Total Assets: 25152000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.24× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	0.22×	Current Assets: 1984155 Open source Current Liabilities: 9093683 Open source
20202020-12-31	Current assets / current liabilities	2.6×	Current Assets: 20394000 Open source Current Liabilities: 7841000 Open source
20212021-12-31	Current assets / current liabilities	3.64×	Current Assets: 27324000 Open source Current Liabilities: 7509000 Open source
20222022-12-31	Current assets / current liabilities	0.8×	Current Assets: 5424000 Open source Current Liabilities: 6813000 Open source
20232023-12-31	Current assets / current liabilities	0.34×	Current Assets: 2461000 Open source Current Liabilities: 7289000 Open source
20242024-12-31	Current assets / current liabilities	1.5×	Current Assets: 7473000 Open source Current Liabilities: 4978000 Open source
20252025-12-31	Current assets / current liabilities	0.24×	Current Assets: 4384000 Open source Current Liabilities: 18076000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 10.75 million Exact value Exact value: -10754319 USD 2019-01-01 – 2019-12-31: -10754319 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2019-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -10754319 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10754319 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315221010362/vvos-20201231.xml#118432 Filing: 000149315221010362 The citation records this snapshot. The page link may show a newer release later.	−USD 5.34 million Exact value Exact value: -5340480 USD 2019-01-01 – 2019-12-31: -5340480 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2019-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -5340480 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5340480 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315221010362/vvos-20201231.xml#136646 Filing: 000149315221010362 The citation records this snapshot. The page link may show a newer release later.	USD 175,599 Exact value Exact value: 175599 USD 2019-01-01 – 2019-12-31: 175599 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2019-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 175599 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 175599 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315221010362/vvos-20201231.xml#144350 Filing: 000149315221010362 The citation records this snapshot. The page link may show a newer release later.	−USD 5.52 million Calculation and evidence -5340480 − 175599 USD Exact free cash flow: -5516079 USD 2019-01-01 – 2019-12-31: -5340480 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 175599 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2019-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -5516079 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5340480 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315221010362/vvos-20201231.xml#136646 Filing: 000149315221010362 Input fundies:CapitalExpenditure: 175599 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315221010362/vvos-20201231.xml#144350 Filing: 000149315221010362 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 12.06 million Exact value Exact value: -12057000 USD 2020-01-01 – 2020-12-31: -12057000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2020-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -12057000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12057000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223002826/forms-1.htm#3688203 Filing: 000149315223002826 The citation records this snapshot. The page link may show a newer release later.	−USD 5.7 million Exact value Exact value: -5700000 USD 2020-01-01 – 2020-12-31: -5700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2020-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -5700000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223002826/forms-1.htm#3180008 Filing: 000149315223002826 The citation records this snapshot. The page link may show a newer release later.	USD 120,000 Exact value Exact value: 120000 USD 2020-01-01 – 2020-12-31: 120000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2020-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 120000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 120000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223002826/forms-1.htm#3033886 Filing: 000149315223002826 The citation records this snapshot. The page link may show a newer release later.	−USD 5.82 million Calculation and evidence -5700000 − 120000 USD Exact free cash flow: -5820000 USD 2020-01-01 – 2020-12-31: -5700000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 120000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2020-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -5820000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223002826/forms-1.htm#3180008 Filing: 000149315223002826 Input fundies:CapitalExpenditure: 120000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223002826/forms-1.htm#3033886 Filing: 000149315223002826 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 20.29 million Exact value Exact value: -20288000 USD 2021-01-01 – 2021-12-31: -20288000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2021-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -20288000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20288000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223042518/forms-1.htm#3423529 Filing: 000149315223042518 The citation records this snapshot. The page link may show a newer release later.	−USD 15.74 million Exact value Exact value: -15735000 USD 2021-01-01 – 2021-12-31: -15735000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2021-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -15735000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15735000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223042518/forms-1.htm#2902368 Filing: 000149315223042518 The citation records this snapshot. The page link may show a newer release later.	USD 2.4 million Exact value Exact value: 2396000 USD 2021-01-01 – 2021-12-31: 2396000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2021-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 2396000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2396000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223042518/forms-1.htm#2905485 Filing: 000149315223042518 The citation records this snapshot. The page link may show a newer release later.	−USD 18.13 million Calculation and evidence -15735000 − 2396000 USD Exact free cash flow: -18131000 USD 2021-01-01 – 2021-12-31: -15735000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2396000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2021-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -18131000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15735000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223042518/forms-1.htm#2902368 Filing: 000149315223042518 Input fundies:CapitalExpenditure: 2396000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315223042518/forms-1.htm#2905485 Filing: 000149315223042518 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 23.85 million Exact value Exact value: -23845000 USD 2022-01-01 – 2022-12-31: -23845000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2022-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -23845000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315224029491/form10-ka.htm#1030801 Filing: 000149315224029491 The citation records this snapshot. The page link may show a newer release later.	−USD 19.6 million Exact value Exact value: -19600000 USD 2022-01-01 – 2022-12-31: -19600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2022-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -19600000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19600000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315224029491/form10-ka.htm#566764 Filing: 000149315224029491 The citation records this snapshot. The page link may show a newer release later.	USD 924,000 Exact value Exact value: 924000 USD 2022-01-01 – 2022-12-31: 924000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2022-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 924000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 924000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315224029491/form10-ka.htm#426938 Filing: 000149315224029491 The citation records this snapshot. The page link may show a newer release later.	−USD 20.52 million Calculation and evidence -19600000 − 924000 USD Exact free cash flow: -20524000 USD 2022-01-01 – 2022-12-31: -19600000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 924000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2022-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -20524000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19600000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315224029491/form10-ka.htm#566764 Filing: 000149315224029491 Input fundies:CapitalExpenditure: 924000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315224029491/form10-ka.htm#426938 Filing: 000149315224029491 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 13.58 million Exact value Exact value: -13583000 USD 2023-01-01 – 2023-12-31: -13583000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2023-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -13583000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13583000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001750/form10-k.htm#1721628 Filing: 000164117225001750 The citation records this snapshot. The page link may show a newer release later.	−USD 11.9 million Exact value Exact value: -11900000 USD 2023-01-01 – 2023-12-31: -11900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2023-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -11900000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11900000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001750/form10-k.htm#1312988 Filing: 000164117225001750 The citation records this snapshot. The page link may show a newer release later.	USD 803,000 Exact value Exact value: 803000 USD 2023-01-01 – 2023-12-31: 803000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2023-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 803000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 803000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001750/form10-k.htm#1180387 Filing: 000164117225001750 The citation records this snapshot. The page link may show a newer release later.	−USD 12.7 million Calculation and evidence -11900000 − 803000 USD Exact free cash flow: -12703000 USD 2023-01-01 – 2023-12-31: -11900000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 803000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2023-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -12703000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11900000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001750/form10-k.htm#1312988 Filing: 000164117225001750 Input fundies:CapitalExpenditure: 803000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001750/form10-k.htm#1180387 Filing: 000164117225001750 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 11.1 million Exact value Exact value: -11100000 USD 2024-01-01 – 2024-12-31: -11100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2024-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -11100000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11100000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1529099 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	−USD 12.7 million Exact value Exact value: -12700000 USD 2024-01-01 – 2024-12-31: -12700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2024-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -12700000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530840 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	USD 568,000 Exact value Exact value: 568000 USD 2024-01-01 – 2024-12-31: 568000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2024-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 568000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 568000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1381280 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	−USD 13.27 million Calculation and evidence -12700000 − 568000 USD Exact free cash flow: -13268000 USD 2024-01-01 – 2024-12-31: -12700000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 568000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2024-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -13268000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530840 Filing: 000149315226016854 Input fundies:CapitalExpenditure: 568000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1381280 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 21.2 million Exact value Exact value: -21200000 USD 2025-01-01 – 2025-12-31: -21200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Net Income: -21200000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1528753 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	−USD 15.3 million Exact value Exact value: -15300000 USD 2025-01-01 – 2025-12-31: -15300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Operating Cash Flow: -15300000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530439 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	USD 2.34 million Exact value Exact value: 2341000 USD 2025-01-01 – 2025-12-31: 2341000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Capital Expenditure: 2341000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2341000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1380932 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.	−USD 17.64 million Calculation and evidence -15300000 − 2341000 USD Exact free cash flow: -17641000 USD 2025-01-01 – 2025-12-31: -15300000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2341000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · VIVOS THERAPEUTICS, INC. · 2025-12-31 VIVOS THERAPEUTICS, INC. (edgar:1716166) Free cash flow: -17641000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:30:04Z Snapshot: 4930b17c628f28571d0be7327d0b5b884d46fb4a90a6f856025f3ede977872d4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1716166?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1530439 Filing: 000149315226016854 Input fundies:CapitalExpenditure: 2341000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/form10-k.htm#1380932 Filing: 000149315226016854 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

45 filings · 1,761 latest values · 1,761 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001716166, 1716166, VVOS, edgar:1716166

Also known as VIVOS THERAPEUTICS, INC., Vivos Therapeutics, Inc., Vivos BioTechnologies, Inc., Vivos Therapeutics, Inc.

VIVOS THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation